

10/594215

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Kazuo SUZUKI et al. : **Mail Stop: PCT**  
Serial No. NEW : Attorney Docket No. 2006\_1634A  
Filed September 26, 2006 :  
INSULIN RESISTANCE-IMPROVING AGENT  
[Corresponding to PCT/JP2005/005472  
Filed March 25, 2005]

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/\_\_\_\_\_; and/or
- ☐ each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**  
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and  
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or  
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. [X] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.  
Serial No. 10/485,217

10/594215

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Kazuo SUZUKI et al.

By Warren M. Cheek, Jr.  
 Warren M. Cheek, Jr.  
 Registration No. 33,367  
 Attorney for Applicants

WMC/dlk  
 Washington, D.C. 20006-1021  
 Telephone (202) 721-8200  
 Facsimile (202) 721-8250  
 September 26, 2006

AP16 Rec'd PCT/PTO 20 SEP 2006

FORM PTO 1449 (modified)

ATTY DOCKET NO.  
2006\_1634ASERIAL NO.  
NEW

10/594215

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)APPLICANT  
Kazuo SUZUKI et al.

Date Submitted to PTO: September 26, 2006

FILING DATE  
September 26, 2006

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,298,497	3/1994	Tschollar et al.			
	AB	2004/0191209	9/2004	Oba			Corresponds to AJ
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AJ	03/011308	2/2003	WO			Abstract
	AK	2002-537390	11/2002	JP			
	AL	00/50414	8/2000	WO			Corresponds to AK
	AM	2003-055235	2/2003	JP			Abstract
	AN						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	A. Garg et al., "Cholestyramine Therapy for Dyslipidemia in Non-Insulin-Dependent Diabetes Mellitus", Ann Intern Med., Vol. 121, pp. 416-422, 1994.
	AP	
	AQ	

EXAMINER

DATE CONSIDERED